Table 3. Multivariate analyses in the Cox proportional hazards model for DFS and DSS.
| Variables | DFS | DSS | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age (per 10 years increase) | 0.83 | 0.68–1.03 | 0.086 | 0.93 | 0.716–1.22 | 0.61 | |
| Clinical stage (III vs. I or II) | 1.46 | 0.90–2.35 | 0.123 | 1.57 | 0.84–2.96 | 0.160 | |
| Subtype | |||||||
| Luminal | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | |
| HER2+ | 0.90 | 0.52–1.55 | 0.702 | 1.01 | 0.44–2.32 | 0.973 | |
| TNBC | 1.14 | 0.68–1.92 | 0.615 | 3.01 | 1.53–5.91 | 0.001 | |
| LVI (present vs. absent) | 1.95 | 1.21–3.16 | 0.006 | 1.84 | 0.96–3.52 | 0.068 | |
| RCB class | |||||||
| 0/pCR | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | |
| I | 2.32 | 0.65–8.28 | 0.194 | 1.93 | 0.39–9.64 | 0.421 | |
| II | 5.15 | 1.80–14.78 | 0.002 | 3.98 | 1.14–13.84 | 0.030 | |
| III | 13.05 | 4.50–37.90 | <0.0001 | 12.31 | 3.47–43.69 | <0.0001 | |
CI, confidence intervals; DFS, disease-free survival; DSS, disease-specific survival; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; LVI, lymphovascular Invasion; RCB, residual cancer burden, pCR, pathologic complete response.